Interstitial cystitis/bladder pain syndrome: diagnosis and management
- 2k Downloads
Introduction and hypothesis
The bladder pain syndrome (BPS) is a spectrum of urological symptoms characterised by bladder pain with typical cystoscopic features. Diagnosis and management of this syndrome may be difficult. There is no evidence-based management approach for the diagnosis or treatment of BPS. The objective of this study was to critically review and summarise the evidence relating to the diagnosis and treatment of the bladder pain syndrome.
A review of published data on the diagnosis and treatment of the BPS was performed. Our search was limited to English-language articles, on the “diagnosis”, and “management” or “treatment” of “interstitial cystitis” and the “bladder pain syndrome” in “humans.”
Frequency, urgency and pain on bladder filling are the most common symptoms of BPS. All urodynamic volumes are reduced in patients with BPS. Associated conditions include psychological distress, depression, history of sexual assault, irritable bowel syndrome and fibromyalgia. Cystoscopy remains the test for definitive diagnosis, with visualisation of haemorrhage on cystoreduction. A multidisciplinary treatment approach is essential in the management of this condition. Orally administered amitriptyline is an efficacious medical treatment for BPS. Intravesical hyaluronic acid and local anaesthetic, with/without hydrodistension are among new treatment strategies. Sacral or pudendal neuromodulation is effective, minimally invasive and safe. Surgery is reserved for refractory cases.
There remains a paucity of evidence for the diagnosis and treatment of BPS. We encountered significant heterogeneity in the assessment of symptoms, duration of treatment and follow up of patients in our literature review.
KeywordsBladder pain syndrome Interstitial cystitis Treatment Management Diagnosis
Bladder pain syndrome
Painful bladder syndrome
Irritable bowel syndrome
Quality of life
The authors would like to acknowledge Dr Danielle O’Leary and Dr Athanasios Didangelos for their help in the preparation and editing of this manuscript.
Funding for project
There was no funding required for completion of this review.
Conflict of interest
- 7.Rovner ES. Interstitial cystitis. Medscape Reference. May 2011. Cited from http://emedicine.medscape.com/article/2055505-overview#a0156
- 10.World Health Organization (1999) 1st International Consultation on Incontinence. Plymbridge Distributors, PlymouthGoogle Scholar
- 38.Daha LK, Lazar D, Simak R, Pflüger H (2007) Is there a relation between urinary interleukin-6 levels and symptoms before and after intra-vesical glycosaminoglycan substitution therapy in patients with bladder pain syndrome/interstitial cystitis? Int Urogynecol J Pelvic Floor Dysfunct 18(12):1449–1452PubMedCrossRefGoogle Scholar
- 43.Sairanen J, Tammela TL, Leppilahti M, Onali M, Forsell T, Ruutu M (2007) Potassium sensitivity test (PST) as a measurement of treatment efficacy of painful bladder syndrome/interstitial cystitis: a prospective study with cyclosporine a and pentosan polysulfate sodium. Neurol Urodyn 26(2):267–270CrossRefGoogle Scholar
- 48.Shie JH, Kuo HC (2011) Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU 108(2):136–141Google Scholar
- 74.Abrahms P, Cardozo L, Khoury S, Wein A. Incontinence. 4th Edition 2009. 4th International Consultation on Incontinence. July 2008.Google Scholar
- 84.Nickel JC, Hanno P, Kumar K, Thomas H (2012) Second multicenter, randomized, double-blind parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology 79(6):1220–1224PubMedCrossRefGoogle Scholar
- 98.Zabihi N, Mourtzinos A, Maher MG, Raz S, Rodriguez LV (2008) Short-term results of bilateral S2-S4 sacral neuromodulation for the treatment of refractory interstitial cystitis, painful bladder syndrome, and chronic pelvic pain. Int Urogynecol J Pelvic Floor Dysfunct 19(4):553–557PubMedCrossRefGoogle Scholar